Hardman & Co Research: Yourgene Health (YGEN): EBITDA-positive in fiscal 2020

Dow Jones received a payment from EQS/DGAP to publish this press release.

Hardman & Co Research 
Hardman & Co Research: Yourgene Health (YGEN): EBITDA-positive in fiscal 2020 
 
22-Feb-2019 / 10:00 GMT/BST 
 
*Hardman & Co: EBITDA-positive in fiscal 2020* 
 
Yourgene Health (YGEN) is an international molecular diagnostics group that 
uses the latest advances in DNA sequencing technology for non-invasive 
prenatal screening tests (NIPT). Its flagship IONA test uses complex 
statistical analyses to determine the likelihood that a fetus is carrying a 
genetic disorder, such as Down's syndrome. YGEN has been held back by a patent 
infringement case and a complicated balance sheet. However, settlement of the 
patent case with Illumina and repayment of debt to Thermo Fisher (TMO) have 
transformed YGEN, allowing it to focus entirely on the enormous global growth 
opportunity for prenatal screening tests. 
 
Please click here for the full report: 
 
https://www.hardmanandco.com/research/corporate-research/ebitda-positive-in-fi 
scal-2020/ [1] 
 
+------------------------+----------------+--------------------+ 
|*To contact us:*        |*Contacts:*     |                    | 
|                        |                |[e-mail] | 
|Hardman & Co            |Dr Martin Hall  |[e-mail]| 
|35 New Broad Street     |Dr Dorothea Hill|[e-mail] | 
|London                  |Dr Gregoire Pave|                    | 
|EC2M 1NH                |                |                    | 
|www.hardmanandco.com    |[phone]|                    | 
|*Follow us on Twitter*  |                |                    | 
|@HardmanandCo           |                |                    | 
+------------------------+----------------+--------------------+ 
 
*Hardman & Co Research can still be accessed for free after MiFID II. Please 
*click here [2] *to read the statement.* 
 
*About Hardman & Co:* For the past 21 years Hardman has been producing 
specialist research designed to improve investors' understanding of companies, 
sectors, industries and investment securities. Our analysts are highly 
experienced in their sectors, and have often been highly rated by professional 
investors for their knowledge. Our focus is to raise companies' profiles 
across the world with high-quality research, investor engagement programmes 
and advisory services. 
 
Hardman Research Ltd, trading as Hardman & Co, is an appointed representative 
of Capital Markets Strategy Ltd and is authorised and regulated by the 
Financial Conduct Authority; our FCA registration number is 600843. Hardman 
Research Ltd is registered at Companies House with number 8256259. 
 
Our research is provided for the use of the professional investment community, 
market counterparties and sophisticated and high net worth investors as 
defined in the rules of the regulatory bodies. It is not intended to be made 
available to unsophisticated retail investors. Anyone who is unsure of their 
categorisation should consult their professional advisors. This research is 
neither an offer, nor a solicitation, to buy or sell any security. Please read 
the note for the full disclaimer. 
 
Dissemination of a CORPORATE NEWS, transmitted by EQS Group. 
The issuer is solely responsible for the content of this announcement. 
End of Announcement - EQS News Service 
 
780067 22-Feb-2019 
 
 
1: https://link.cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=e460b833c5b3605c1672165f6489dc52&application_id=780067&site_id=vwd&application_name=news 
2: https://link.cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=5a632f52f80bd372265e4041a743aa1c&application_id=780067&site_id=vwd&application_name=news 
 

(END) Dow Jones Newswires

February 22, 2019 05:00 ET (10:00 GMT)